Longboard Pharmaceuticals, (id:6754 LBPH)
59.80 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/24/2024 1:53:50 AM)
Exchange closed, opens in 1 day 7 hours
0.00 USD (0.00%)
0.07 USD (0.07%)
1.12 USD (1.12%)
217.07 USD (217.07%)
1,293.94 USD (1,293.94%)
273.75 USD (273.75%)
About Longboard Pharmaceuticals,
Market Capitalization 2.33B
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.
| Headquarters (address) |
4275 Executive Square La Jolla 92037 CA United States |
| Phone | 858 789 9283 |
| Website | https://www.longboardpharma.com |
| Employees | 50 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | LBPH |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 3.60 - 59.95 |
| Market Capitalization | 2.33B |
| P/E trailing | -25.01 |
| P/E forward | -21.21 |
| Price/Book | 8.48 |
| Beta | 1.09 |
| EPS | -2.25 |
| EPS United States (ID:6, base:3403) | 24.22 |